- Home
- ACHR vs BPMC Comparison
ACHR vs BPMC Comparison
Compare ACHR & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHR
- BPMC
- Stock Information
- Founded
- ACHR 2018
- BPMC 2008
- Country
- ACHR United States
- BPMC United States
- Employees
- ACHR N/A
- BPMC N/A
- Industry
- ACHR Aerospace
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- ACHR Industrials
- BPMC Health Care
- Exchange
- ACHR Nasdaq
- BPMC Nasdaq
- Market Cap
- ACHR 6.4B
- BPMC 5.8B
- IPO Year
- ACHR N/A
- BPMC 2015
- Fundamental
- Price
- ACHR $10.14
- BPMC $128.20
- Analyst Decision
- ACHR Strong Buy
- BPMC Buy
- Analyst Count
- ACHR 8
- BPMC 20
- Target Price
- ACHR $13.13
- BPMC $127.82
- AVG Volume (30 Days)
- ACHR 38.9M
- BPMC 6.4M
- Earning Date
- ACHR 08-07-2025
- BPMC 07-31-2025
- Dividend Yield
- ACHR N/A
- BPMC N/A
- EPS Growth
- ACHR N/A
- BPMC N/A
- EPS
- ACHR N/A
- BPMC N/A
- Revenue
- ACHR N/A
- BPMC $562,121,000.00
- Revenue This Year
- ACHR N/A
- BPMC $44.46
- Revenue Next Year
- ACHR N/A
- BPMC $32.78
- P/E Ratio
- ACHR N/A
- BPMC N/A
- Revenue Growth
- ACHR N/A
- BPMC 99.19
- 52 Week Low
- ACHR $2.82
- BPMC $73.04
- 52 Week High
- ACHR $13.92
- BPMC $128.34
- Technical
- Relative Strength Index (RSI)
- ACHR 49.95
- BPMC 75.62
- Support Level
- ACHR $9.88
- BPMC $127.86
- Resistance Level
- ACHR $10.61
- BPMC $128.33
- Average True Range (ATR)
- ACHR 0.64
- BPMC 0.41
- MACD
- ACHR -0.13
- BPMC -0.32
- Stochastic Oscillator
- ACHR 31.91
- BPMC 84.62
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.